News releases Back to the news list January 25, 2010 Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer Please see PDF file attached.

Term and conditions of use. Safe harbor and privacy policy. Copyright © 2004 Æterna Zentaris Inc. All rights reserved. Use of this site signifies your agreement to the terms of use.